Prostate cancer combo trial pulled before it began
NCT ID NCT06528210
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study was designed to test whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard hormone therapy and radiation could improve outcomes for men with high-risk localized prostate cancer. The trial was withdrawn before enrolling any participants, so no results are available. The goal was to see if the combination could eliminate cancer cells in the prostate and control the disease long-term.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab (Keytruda) plus hormone therapy (bicalutamide and GnRH agonists) and radiation therapy
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH RISK PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug plus precision radiation stop prostate cancer from spreading?
- Hormone therapy plus precision radiation aims to crush prostate cancer early
- Can a 5-Day proton blast beat prostate cancer for good?
- Double-Dose precision: new combo radiation aims to shrink prostate tumors faster
- Talking about sex after cancer: telehealth therapy may improve recovery
- New scan could spot hidden aggressive prostate cancer in men who think They're safe